Prostaglandin E1-d4

Prostaglandin E₁-d₄

Cayman Chemical Item Number 313010

Alprostadil-d₄; PGE₁-d₄

Description

Prostaglandin E₁-d₄ (PGE₁-d₄) contains four deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGE₁ by GC- or LC-mass spectrometry. PGE₁ is the theoretical cyclooxygenase metabolite of dihomo-γ-linolenic acid (DGLA), but it is virtually undetectable in the plasma of normal humans or other animals.¹ Its pharmacology includes vasodilation, hypotension, and anti-platelet activities. The IC₅₀ of PGE₁ for the inhibition of ADP-induced human platelet aggregation is 40 nM.^2,3 The vasorelaxant and anti-hypertensive effects of PGE₁ are used to treat male erectile dysfunction and to provide emergency vasodilation of the patent ductus arteriosus in infants whose cardiac anomalies require pulmonary shunting for survival.^4,5 In human males, the intracavernosal effective dose range for PGE₁ is 2 to 80 µg, and the transurethral range is 125 to 1,000 µg.⁴

1 Cawello, W., Schweer, H., Dietrich, B., et al. Pharmacokinetics of prostaglandin E₁ and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E₁ in patients with erectile dysfunction. J Urol 158 1403-1407 (1997).

2 Kobzar, G., Mardla, V., Järving, I., et al. Antiaggregating potency of E-type prostaglandins in human and rabbit platelets. Proc Est Acad Sci Chem 40 179-180 (1991).

3 Okada, F., Nukada, T., Yamauchi, Y., et al. The hypotensive effect of prostaglandin E₁ on hypertensive cases of various types. Prostaglandins 7 99-106 (1974).

4 Padma-Nathan, H., Hellstrom, W.J.G., Kaiser, F.E., et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 336 1-7 (1997).

5 Olley, P.M., and Coceani, F. Prostaglandins and the ductus arteriosus. Annu Rev Med 32 375-3785 (1981).

Synonyms

Alprostadil-d4
PGE1-d4

Formal Name

9-oxo-11α,15S-dihydroxy-prost-13E-en-1-oic-3,3,4,4-d4 acid

Molecular Formula

C₂₀H₃₀D₄O₅

Formula Weight

358.5

Formulation

A solution in methyl acetate

Purity

≥99% deuterated forms (d1-d4)

Stability

1 year

Storage

-20°C

Shipping

Wet ice in continental US; may vary elsewhere

SMILES

Copy SMILES to clipboard

CCCCCCCC1C(=O)CC(O)[C@@H]1\C=C\C(O)CCCCC

Background Reading

Kobzar, G., Mardla, V., Järving, I., et al. Antiaggregating potency of E-type prostaglandins in human and rabbit platelets. Proc Est Acad Sci Chem 40 179-180 (1991).

Olley, P.M., and Coceani, F. Prostaglandins and the ductus arteriosus. Annu Rev Med 32 375-3785 (1981).

Cawello, W., Schweer, H., Dietrich, B., et al. Pharmacokinetics of prostaglandin E₁ and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E₁ in patients with erectile dysfunction. J Urol 158 1403-1407 (1997).

Okada, F., Nukada, T., Yamauchi, Y., et al. The hypotensive effect of prostaglandin E₁ on hypertensive cases of various types. Prostaglandins 7 99-106 (1974).

Padma-Nathan, H., Hellstrom, W.J.G., Kaiser, F.E., et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 336 1-7 (1997).

Show all 5 Hide all but first 3

Size

Price

Quantity

Subtotal

50 µg 
$42.00

$0.00

100 µg 
$80.00

$0.00

500 µg 
$336.00

$0.00

5 mg 
$2,520.00

$0.00

Bulk
Contact

Cart Total

$0.00

Other Resources

Management Team Company Profile Company History ChemAssistant Tools FAQs

Cayman Europe Cayman Pharma CaBRI Cayman Gear Press Releases

Illustrations and Charts Key Research Area Posters Article Library Analysis Tools Conference Schedule

Order Terms Browser Recommendation Privacy Statement Site Map

Prostaglandin E₁-d₄